価格
  1. 米国企業
  2. 9 METERS BIOPHARMA, INC.
  3. Raw

9 METERS BIOPHARMA, INC.【NMTRQ】

時価総額
$1445.97
PER
希少消化器疾患向け治療薬の新興企業。Phase3の長時間作用GLP-1作動薬vurolenatideを中心とした開発。22年12月末の現金約1260万ドルと23年3月の増資で約440万ドルの資金調達。米国中心に展開。
株価業績
サマリーテーブルに戻る
2016年
12月31日		2017年
12月31日		2018年
12月31日		2019年
12月31日		2020年
12月31日		2021年
12月31日		2022年
12月31日
Net loss-6-8-24,162,279-27,048,808-61,496,489-36,779,400-43,766,415
Share-based compensation1143524
Amortization of debt discount--31243,9832
Depreciation--19,55521,60718,4917,5738,523
Noncash Research And Development In Process-----3-
Change in fair value of derivative liability---50,000-873,000-771,000-7,000-437,000
Non-Cash Milestone Fees------500,000
Loss on extinguishment of convertible note payable-------20,645
Prepaid expenses and other assets--298,72450,145445,5352368,669
Accounts payable-1086,412124,973-2,465,07413
Accrued expenses and other liabilities-------1,588,529
Accrued interest----101,624488-488-
Net cash used in operating activities--4-15,169,330-17,967,992-19,409,786-29,478,275-37,243,217
Purchase of property and equipment--13,94311,9342,54312,4762,842
Purchase of in-process research and development, net of assets acquired----32-
Maturity of restricted deposit-----75,000-
Net cash used in investing activities---13,943-11,934-3,186,997-2,430,641-2,842
Proceeds from Notes Payable--353-21
Payments of debt issuance costs0-50,00057,00023,000-1
Payments of convertible notes-----58,199-
Proceeds from Issuance of Common Stock1018213735-
Proceeds from Stock Options Exercised--182,42830,064-346,961-
Proceeds from Warrant Exercises--928,178-39-
Payment of offering costs1-1163-
Net cash provided by financing activities-32117564120
Net (decrease) increase in cash, cash equivalents and restricted cash----1,135,968339-17,334,353
Cash paid during the year for interest00280,287874,20362,912569835,038
Stock Issued--9-5-105,342
Noncash Addition Of Derivative Liability----370,000-2